This episode of The Cutaneous Connection podcast, sponsored by Incyte, explores the world of vitiligo. From symptoms to current treatment dissatisfaction and the latest research, Pearl Grimes, MD, FAAD, explains where we are now with this pigmentary disorder and where we are headed.

In this episode, we sit down with the OJM Group from Cincinnati, Ohio, to discuss qualified retirement plans and how many dermatology practices could be saving money. 

We dive into the background of the “The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas.” Adam Friedman, MD, and Misty Eleryan MD, MS, describe their process to creating this new dermatologic resource. 

This episode of The Cutaneous Connection podcast, Gary Linkov, MD, dives into the topic of hair loss. 

In this episode, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and why physicians should educate their patients about this type of inflammation.

This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab sets itself apart from other biologics in the pipeline for psoriasis.

This episode takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. Mark Lebwohl, MD, discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class. 

In this episode, Assistant Editor Linda Stocum sits down with Jennifer Powers, MD, board certified dermatologist and associate professor of dermatology at the University of Iowa, to discuss her recent research exploring how diet and supplements affect patients with mild psoriasis.

In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).

In this episode, we provide an update on a story we broke regarding benzene contamination being detected in various sunscreens and after-sun care products. Now, Johnson & Johnson has conducted its own internal testing and is recalling 5 different aerosol sunscreen products from Neutrogena and Aveeno. Listen as Christopher Bunick, MD, explains what this means for the sun protection industry and the next steps for the FDA.